While increased immune responses were observed using IL-2 as an adjuvant, altered levels of IL-2 have been found in inflammatory bowel disease patients and the complex interaction IL-2 has between inducing tolerance versus inflammation may be problematic for its use as a mucosal adjuvant [56,57,58]. The gene discussed is IL2; the disease is inflammatory bowel disease.